Page 8 of 14 – SEC Filing CUSIP No. 87184Q107 13G Page 8 of 11
Item 1(a). Name of Issuer: Syros Pharmaceuticals, Inc. Item 1(b). Address of Issuer’s Principal Executive Offices: 620 Memorial Drive, Suite 300 Cambridge, MA 02139 Item 2(a). Name of Person Filing: James E. Flynn, Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Management Company, L.P., Deerfield Special Situations Fund, L.P. and Deerfield Private Design Fund III, L.P. Item 2(b). Address of Principal Business Office, or if None, Residence: James E. Flynn, Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Management Company, L.P., Deerfield Special Situations Fund, L.P., and Deerfield Private Design Fund III, L.P., 780 Third Avenue, 37th Floor, New York, NY 10017 Item 2(c). Citizenship: Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Management Company, L.P., Deerfield Private Design Fund III, L.P. and Deerfield Special Situations Fund, L.P. – Delaware limited partnerships; James E. Flynn – United States citizen Item 2(d). Title of Class of Securities: Common Stock, par value $0.001 per share Item 2(e). CUSIP Number: 87184Q107 Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
(a) o Broker or dealer registered under Section 15 of the Exchange Act. (b) o Bank as defined in Section 3(a)(6) of the Exchange Act. (c) o Insurance company as defined in Section 3(a)(19) of the Exchange Act. (d) o Investment company registered under Section 8 of the Investment Company Act.
(e) o An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
Follow Syros Pharmaceuticals Inc.
Follow Syros Pharmaceuticals Inc.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
| CUSIP No. | 87184Q107 | 13G | Page 8 of 11 |
| Item 1(a). | Name of Issuer: | |
| Syros Pharmaceuticals, Inc. | ||
| Item 1(b). | Address of Issuer’s Principal Executive Offices: | |
| 620 Memorial Drive, Suite 300 Cambridge, MA 02139 | ||
| Item 2(a). | Name of Person Filing: | |
| James E. Flynn, Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Management Company, L.P., Deerfield Special Situations Fund, L.P. and Deerfield Private Design Fund III, L.P. | ||
| Item 2(b). | Address of Principal Business Office, or if None, Residence: | |
| James E. Flynn, Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Management Company, L.P., Deerfield Special Situations Fund, L.P., and Deerfield Private Design Fund III, L.P., 780 Third Avenue, 37th Floor, New York, NY 10017 | ||
| Item 2(c). | Citizenship: | |
| Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Management Company, L.P., Deerfield Private Design Fund III, L.P. and Deerfield Special Situations Fund, L.P. – Delaware limited partnerships; James E. Flynn – United States citizen | ||
| Item 2(d). | Title of Class of Securities: | |
| Common Stock, par value $0.001 per share | ||
| Item 2(e). | CUSIP Number: | |
| 87184Q107 | ||
| Item 3. | If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: |
| (a) | o | Broker or dealer registered under Section 15 of the Exchange Act. | |
| (b) | o | Bank as defined in Section 3(a)(6) of the Exchange Act. | |
| (c) | o | Insurance company as defined in Section 3(a)(19) of the Exchange Act. | |
| (d) | o | Investment company registered under Section 8 of the Investment Company Act. |
| (e) | o | An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); |
Follow Syros Pharmaceuticals Inc.
Follow Syros Pharmaceuticals Inc.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.